熱門資訊> 正文
Ascendis获得FDA批准用于治疗生长激素缺乏症
2025-07-29 00:09
- The U.S. FDA has approved Ascendis Pharma's (ASND) Skytrofa (lonapegsomatropin) as a once-weekly treatment for adults with growth hormone deficiency (GHD).
- Skytrofa, which acts as a replacement of endogenous growth hormone, was previously approved by the agency in 2021 as a pediatric GHD therapy.
- Approval was based on the results of a phase 3 trial that compared the efficacy of weekly Skytrofa, also known as TransCon hGH, with daily somatropin weekly placebo and in adults with GHD.
More on Ascendis Pharma
- Ascendis Pharma A/S (ASND) Q1 2025 Earnings Call Transcript
- Ascendis Pharma reports positive results from hypothyroid trial
- Ascendis rises after FDA priority review for genetic condition treatment
- Seeking Alpha’s Quant Rating on Ascendis Pharma
- Historical earnings data for Ascendis Pharma
風險及免責提示:以上內容僅代表作者的個人立場和觀點,不代表華盛的任何立場,華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前,應結合自身情況,考慮投資產品的風險。必要時,請諮詢專業投資顧問的意見。華盛不提供任何投資建議,對此亦不做任何承諾和保證。